




EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

ANTIMICROBIAL RESISTANCE

OVERVIEW OF EMA ACTIVITIES

Presented by Dr. Radu Botgros
Senior Scientific Officer, Health Threats and Vaccines Strategy
European Medicines Agency



An agency of the European Union





DEFINITIONS (for completeness)

Antimicrobial=antibiotic/antiviral/antifungal/antiprotozoal

- Active substances of natural or synthetic origin that kill or inhibit the growth of microorganisms.

Antimicrobial resistance (AMR)= the ability of microorganisms of becoming increasingly resistant to an antimicrobial (to which they were previously susceptible)

- A consequence of natural selection, therefore unavoidable when using the drug
 - Exacerbated by human factors: inappropriate use in humans and animals, inadequate practices in the food chain and in health care settings etc.
- Genetic mutations conferring resistance (some that can be passed between the microorganisms)





Sir Alexander Fleming FRS FRSE FRCS (1881–1955)

ALEXANDER FLEMING

Penicillin

Nobel Lecture, December 11, 1945

"...But I would like to sound one note of warning. [...] **It is not difficult to make microbes resistant to penicillin** in the laboratory by exposing them to concentrations not sufficient to kill them, and the same thing has occasionally happened in the body. **The time may come when penicillin can be bought by anyone in the shops.** Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug **make them resistant.**"

...and has become a global One Health threat



EUROPEAN MEDICINES AGENCY

ANTIBIOTIC RESISTANCE THE GLOBAL THREAT

Antibiotic resistance – when bacteria change and cause antibiotics to fail – is happening **RIGHT NOW**, across the world


The full impact is unknown. There is no system in place to track antibiotic resistance globally



Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats.



ANTIBIOTIC RESISTANCE HOW IT SPREADS




www.who.int/drugresistance

#AntibioticResistance






AMR as perceived by the general public a short while ago



WHO multi-country survey reveals widespread public misunderstanding about antibiotic resistance

On 16 November 2012, the World Health Organization (WHO) published the results of a multi-country survey that reveals that people are confused about the cause of antibiotic resistance, how it spreads, and how to prevent it. Antibiotic resistance happens when bacteria change and become resistant to the antibiotics used to treat the infections they cause. This can happen in people and animals because of the development of resistant bacteria, and the growing number and use of antibiotics. People are often confused about the cause of antibiotic resistance, how it spreads, and how to prevent it. The survey findings indicate that the public is often confused about the cause of antibiotic resistance, how it spreads, and how to prevent it. The survey findings indicate that the public is often confused about the cause of antibiotic resistance, how it spreads, and how to prevent it.

2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
1967
1966
1965
1964
1963
1962
1961
1960
1959
1958
1957
1956
1955
1954
1953
1952
1951
1950
1949
1948
1947
1946
1945
1944
1943
1942
1941
1940
1939
1938
1937
1936
1935
1934
1933
1932
1931
1930
1929
1928
1927
1926
1925
1924
1923
1922
1921
1920
1919
1918
1917
1916
1915
1914
1913
1912
1911
1910
1909
1908
1907
1906
1905
1904
1903
1902
1901
1900
1899
1898
1897
1896
1895
1894
1893
1892
1891
1890
1889
1888
1887
1886
1885
1884
1883
1882
1881
1880
1879
1878
1877
1876
1875
1874
1873
1872
1871
1870
1869
1868
1867
1866
1865
1864
1863
1862
1861
1860
1859
1858
1857
1856
1855
1854
1853
1852
1851
1850
1849
1848
1847
1846
1845
1844
1843
1842
1841
1840
1839
1838
1837
1836
1835
1834
1833
1832
1831
1830
1829
1828
1827
1826
1825
1824
1823
1822
1821
1820
1819
1818
1817
1816
1815
1814
1813
1812
1811
1810
1809
1808
1807
1806
1805
1804
1803
1802
1801
1800
1799
1798
1797
1796
1795
1794
1793
1792
1791
1790
1789
1788
1787
1786
1785
1784
1783
1782
1781
1780
1779
1778
1777
1776
1775
1774
1773
1772
1771
1770
1769
1768
1767
1766
1765
1764
1763
1762
1761
1760
1759
1758
1757
1756
1755
1754
1753
1752
1751
1750
1749
1748
1747
1746
1745
1744
1743
1742
1741
1740
1739
1738
1737
1736
1735
1734
1733
1732
1731
1730
1729
1728
1727
1726
1725
1724
1723
1722
1721
1720
1719
1718
1717
1716
1715
1714
1713
1712
1711
1710
1709
1708
1707
1706
1705
1704
1703
1702
1701
1700
1699
1698
1697
1696
1695
1694
1693
1692
1691
1690
1689
1688
1687
1686
1685
1684
1683
1682
1681
1680
1679
1678
1677
1676
1675
1674
1673
1672
1671
1670
1669
1668
1667
1666
1665
1664
1663
1662
1661
1660
1659
1658
1657
1656
1655
1654
1653
1652
1651
1650
1649
1648
1647
1646
1645
1644
1643
1642
1641
1640
1639
1638
1637
1636
1635
1634
1633
1632
1631
1630
1629
1628
1627
1626
1625
1624
1623
1622
1621
1620
1619
1618
1617
1616
1615
1614
1613
1612
1611
1610
1609
1608
1607
1606
1605
1604
1603
1602
1601
1600
1599
1598
1597
1596
1595
1594
1593
1592
1591
1590
1589
1588
1587
1586
1585
1584
1583
1582
1581
1580
1579
1578
1577
1576
1575
1574
1573
1572
1571
1570
1569
1568
1567
1566
1565
1564
1563
1562
1561
1560
1559
1558
1557
1556
1555
1554
1553
1552
1551
1550
1549
1548
1547
1546
1545
1544
1543
1542
1541
1540
1539
1538
1537
1536
1535
1534
1533
1532
1531
1530
1529
1528
1527
1526
1525
1524
1523
1522
1521
1520
1519
1518
1517
1516
1515
1514
1513
1512
1511
1510
1509
1508
1507
1506
1505
1504
1503
1502
1501
1500
1499
1498
1497
1496
1495
1494
1493
1492
1491
1490
1489
1488
1487
1486
1485
1484
1483
1482
1481
1480
1479
1478
1477
1476
1475
1474
1473
1472
1471
1470
1469
1468
1467
1466
1465
1464
1463
1462
1461
1460
1459
1458
1457
1456
1455
1454
1453
1452
1451
1450
1449
1448
1447
1446
1445
1444
1443
1442
1441
1440
1439
1438
1437
1436
1435
1434
1433
1432
1431
1430
1429
1428
1427
1426
1425
1424
1423
1422
1421
1420
1419
1418
1417
1416
1415
1414
1413
1412
1411
1410
1409
1408
1407
1406
1405
1404
1403
1402
1401
1400
1399
1398
1397
1396
1395
1394
1393
1392
1391
1390
1389
1388
1387
1386
1385
1384
1383
1382
1381
1380
1379
1378
1377
1376
1375
1374
1373
1372
1371
1370
1369
1368
1367
1366
1365
1364
1363
1362
1361
1360
1359
1358
1357
1356
1355
1354
1353
1352
1351
1350
1349
1348
1347
1346
1345
1344
1343
1342
1341
1340
1339
1338
1337
1336
1335
1334
1333
1332
1331
1330
1329
1328
1327
1326
1325
1324
1323
1322
1321
1320
1319
1318
1317
1316
1315
1314
1313
1312
1311
1310
1309
1308
1307
1306
1305
1304
1303
1302
1301
1300
1299
1298
1297
1296
1295
1294
1293
1292
1291
1290
1289
1288
1287
1286
1285
1284
1283
1282
1281
1280
1279
1278
1277
1276
1275
1274
1273
1272
1271
1270
1269
1268
1267
1266
1265
1264
1263
1262
1261
1260
1259
1258
1257
1256
1255
1254
1253
1252
1251
1250
1249
1248
1247
1246
1245
1244
1243
1242
1241
1240
1239
1238
1237
1236
1235
1234
1233
1232
1231
1230
1229
1228
1227
1226
1225
1224
1223
1222
1221
1220
1219
1218
1217
1216
1215
1214
1213
1212
1211
1210
1209
1208
1207
1206
1205
1204
1203
1202
1201
1200
1199
1198
1197
1196
1195
1194
1193
1192
1191
1190
1189
1188
1187
1186
1185
1184
1183
1182
1181
1180
1179
1178
1177
1176
1175
1174
1173
1172
1171
1170
1169
1168
1167
1166
1165
1164
1163
1162
1161
1160
1159
1158
1157
1156
1155
1154
1153
1152
1151
1150
1149
1148
1147
1146
1145
1144
1143
1142
1141
1140
1139
1138
1137
1136
1135
1134
1133
1132
1131
1130
1129
1128
1127
1126
1125
1124
1123
1122
1121
1120
1119
1118
1117
1116
1115
1114
1113
1112
1111
1110
1109
1108
1107
1106
1105
1104
1103
1102
1101
1100
1099
1098
1097
1096
1095
1094
1093
1092
1091
1090
1089
1088
1087
1086
1085
1084
1083
1082
1081
1080
1079
1078
1077
1076
1075
1074
1073
1072
1071
1070
1069
1068
1067
1066
1065
1064
1063
1062
1061
1060
1059
1058
1057
1056
1055
1054
1053
1052
1051
1050
1049
1048
1047
1046
1045
1044
1043
1042
1041
1040
1039
1038
1037
1036
1035
1034
1033
1032
1031
1030
1029
1028
1027
1026
1025
1024
1023
1022
1021
1020
1019
1018
1017
1016
1015
1014
1013
1012
1011
1010
1009
1008
1007
1006
1005
1004
1003
1002
1001
1000
999
998
997
996
995
994
993
992
991
990
989
988
987
986
985
984
983
982
981
980
979
978
977
976
975
974
973
972
971
970
969
968
967
966
965
964
963
962
961
960
959
958
957
956
955
954
953
952
951
950
949
948
947
946
945
944
943
942
941
940
939
938
937
936
935
934
933
932
931
930
929
928
927
926
925
924
923
922
921
920
919
918
917
916
915
914
913
912
911
910
909
908
907
906
905
904
903
902
901
900
899
898
897
896
895
894
893
892
891
890
889
888
887
886
885
884
883
882
881
880
879
878
877
876
875
874
873
872
871
870
869
868
867
866
865
864
863
862
861
860
859
858
857
856
855
854
853
852
851
850
849
848
847
846
845
844
843
842
841
840
839
838
837
836
835
834
833
832
831
830
829
828
827
826
825
824
823
822
821
820
819
818
817
816
815
814
813
812
811
810
809
808
807
806
805
804
803
802
801
800
799
798
797
796
795
794
793
792
791
790
789
788
787
786
785
784
783
782
781
780
779
778
777
776
775
774
773
772
771
770
769
768
767
766
765
764
763
762
761
760
759
758
757
756
755
754
753
752
751
750
749
748
747
746
745
744
743
742
741
740
739
738
737
736
735
734
733
732
731
730
729
728
727
726
725
724
723
722
721
720
719
718
717
716
715
714
713
712
711
710
709
708
707
706
705
704
703
702
701
700
699
698
697
696
695
694
693
692
691
690
689
688
687
686
685
684
683
682
681
680
679
678
677
676
675
674
673
672
671
670
669
668
667
666
665
664
663
662
661
660
659
658
657
656
655
654
653
652
651
650
649
648
647
646
645
644
643
642
641
640
639
638
637
636
635
634
633
632
631
630
629
628
627
626
625
624
623
622
621
620
619
618
617
616
615
614
613
612
611
610
609
608
607
606
605
604
603
602
601
600
599
598
597
596
595
594
593
592
591
590
589
588
587
586
585
584
583
582
581
580
579
578
577
576
575
574
573
572
571
570
569
568
567
566
565
564
563
562
561
560
559
558
557
556
555
554
553
552
551
550
549
548
547
546
545
544
543
542
541
540
539
538
537
536
535
534
533
532
531
530
529
528
527
526
525
524
523
522
521
520
519
518
517
516
515
514
513
512
511
510
509
508
507
506
505
504
503
502
501
500
499
498
497
496
495
494
493
492
491
490
489
488
487
486
485
484
483
482
481
480
479
478
477
476
475
474
473
472
471
470
469
468
467
466
465
464
463
462
461
460
459
458
457
456
455
454
453
452
451
450
449
448
447
446
445
444
443
442
441
440
439
438
437
436
435
434
433
432
431
430
429
428
427
426
425
424
423
422
421
420
419
418
417
416
415
414
413
412
411
410
409
408
407
406
405
404
403
402
401
400
399
398
397
396
395
394
393
392
391
390
389
388
387
386
385
384
383
382
381
380
379
378
377
376
375
374
373
372
371
370
369
368
367
366
365
364
363
362
361
360
359
358
357
356
355
354
353
352
351
350
349
348
347
346
345
344
343
342
341
340
339
338
337
336
335
334
333
332
331
330
329
328
327
326
325
324
323
322
321
320
319
318
317
316
315
314
313
312
311
310
309
308
307
306
305
304
303
302
301
300
299
298
297
296
295
294
293
292
291
290
289
288
287
286
285
284
283
282
281
280
279
278
277
276
275
274
273
272
271
270
269
268
267
266
265
264
263
262
261
260
259
258
257
256
255
254
253
252
251
250
249
248
247
246
245
244
243
242
241
240
239
238
237
236
235
234
233
232
231
230
229
228
227
226
225
224
223
222
221
220
219
218
217
216
215
214
213
212
211
210
209
208
207
206
205
204
203
202
201
200
199
198
197
196
195
194
193
192
191
190
189
188
187
186
185
184
183
182
181
180
179
178
177
176
175
174
173
172
171
170
169
168
167
166
165
164
163
162
161
160
159
158
157
156
155
154
153
152
151
150
149
148
147
146
145
144
143
142
141
140
139
138
137
136
135
134
133
132
131
130
129
128
127
126
125
124
123
122
121
120
119
118
117
116
115
114
113
112
111
110
109
108
107
106
105
104
103
102
101
100
99
98
97
96
95
94
93
92
91
90
89
88
87
86
85
84
83
82
81
80
79
78
77
76
75
74
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0



- Three quarters (76%) of respondents think that antibiotic resistance happens when the body becomes resistant to antibiotics. In fact bacteria—not humans or animals—become resistant to antibiotics and their spread causes hard-to-treat infections.
- Two thirds (66%) of respondents believe that individuals are not at risk of a drug-resistant infection if they personally take their antibiotics as prescribed. Nearly half (44%) of people surveyed think antibiotic resistance is only a problem for people who take antibiotics regularly. In fact, anyone, of any age, in any country can get an antibiotic-resistant infection.
- More than half (57%) of respondents feel there is not much they can do to stop antibiotic resistance, while nearly two thirds (64%) believe medical experts will solve the problem before it becomes too serious.

AMR: today's figures

33000 people die every year due to infections with antibiotic-resistant bacteria

News story
6 Nov 2018



An ECDC study estimates the burden of five types of infections caused by antibiotic-resistant bacteria of public health concern in the European Union and in the European Economic Area (EU/EEA).

TOP GLOBAL INFECTIOUS DISEASE THREATS DEATHS IN 2019



Deaths reported by the CDC, WHO and GRAM Paper
<https://bit.ly/3GMzVOS> <https://bit.ly/3Kw58Hu> <https://bit.ly/3AfXywb>

If no effective action is put in place, AMR to second-line antibiotics will be 72% higher in 2030 compared to 2005 in the EU/EEA. In the same period, AMR to last-line treatments will more than double.

GLOBAL

A failure to address the problem of antibiotic resistance could result in:



Costing \$100 trillion in economic output



Antimicrobial resistance now a leading cause of death worldwide, study finds

Lancet analysis highlights need for urgent action to address antibiotic-resistant bacterial infections



© A researcher holds up two culture plates growing bacteria in the presence of discs containing various antibiotics. The one on the right has a strain that is resistant to all antibiotics tested. Photograph: Science History Images/Alamy

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Antimicrobial Resistance Collaborators*

Summary

Background Antimicrobial resistance (AMR) poses a major threat to human health around the world. Previous publications have estimated the effect of AMR on incidence, deaths, hospital length of stay, and health-care costs for specific pathogen–drug combinations in select locations. To our knowledge, this study presents the most comprehensive estimates of AMR burden to date.

Methods We estimated deaths and disability-adjusted life-years (DALYs) attributable to and associated with bacterial AMR for 23 pathogens and 88 pathogen–drug combinations in 204 countries and territories in 2019. We obtained data from systematic literature reviews, hospital systems, surveillance systems, and other sources, covering 471 million individual records or isolates and 7585 study-locations-years. We used predictive statistical modelling to produce estimates of AMR burden for all locations, including for locations with no data. Our approach can be divided into five broad components: number of deaths where infection played a role, proportion of infectious deaths attributable to a given infectious syndrome, proportion of infectious syndrome deaths attributable to a given pathogen, the percentage of a given pathogen resistant to an antibiotic of interest, and the excess risk of death or duration of an infection associated with this resistance. Using these components, we estimated disease burden based on two counterfactuals: deaths attributable to AMR (based on an alternative scenario in which all drug-resistant infections were replaced by drug-susceptible infections), and deaths associated with AMR (based on an alternative scenario in which all drug-resistant infections were replaced by no infection). We generated 95% uncertainty intervals (UIs) for final estimates as the 25th and 975th ordered values across 1000 posterior draws, and models were cross-validated for out-of-sample predictive validity. We present final estimates aggregated to the global and regional level.





Figure 3: Global deaths (counts) attributable to and associated with bacterial antimicrobial resistance by infectious syndrome, 2019
 Estimates were aggregated across drugs, accounting for the co-occurrence of resistance to multiple drugs. Error bars show 95% uncertainty intervals. Does not include gonorrhoea and chlamydia because we did not estimate the fatal burden of this infectious syndrome. Bone†=infections of bones, joints, and related organs. BSI=bloodstream infections. Cardiac=endocarditis and other cardiac infections. CNS=meningitis and other bacterial CNS infections. Intra-abdominal=peritoneal and intra-abdominal infections. LRI=lower respiratory infections and all related infections in the thorax. Skin= bacterial infections of the skin and subcutaneous systems. TF-PF-INTS= typhoid fever, paratyphoid fever, and invasive non-typhoidal *Salmonella* spp. UTI=urinary tract infections and pyelonephritis.

AMR: grim forecast for the future

Deaths attributable to antimicrobial resistance every year compared to other major causes of death



Source: Review on Antimicrobial Resistance 2014 updated 2022



← Tweet




Prof. Dame Sally Davies
@UKAMREnvoy

The 'silent pandemic' is not silent anymore.

Predicted deaths due to antimicrobial resistance 2015-2050

AMR mortality rate per 100,000 persons



Source: OECD (2018), Stemming the Superbug Tide: Just A Few Dollars More

On the upside: AMR has made it to the political Agenda...



EUROPEAN MEDICINES AGENCY

ANTIMICROBIAL RESISTANCE: NEW EU ONE HEALTH ACTION PLAN



MAKING THE EU A BEST
PRACTICE REGION ON AMR



BOOSTING RESEARCH,
DEVELOPMENT &
INNOVATION ON AMR



SHAPING THE GLOBAL
AGENDA ON AMR



#EUAMRaction



the core multilateral initiative, is an important component to this end. In this regard, we want to continue to support vaccination rollouts and **local vaccination production in developing countries**. Moreover, we want to step up our efforts to **tackle antimicrobial resistance (AMR)** – the “silent pandemic” that is already under way – and to develop appropriate medical countermeasures.



G7 GERMANY
2022

DRUG RESISTANCE


Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders Group

The WHO has joined forces with the FAO and OIE to establish a new Global Leaders Group on AMR. With members including Merck CEO Kenneth Frazier, the Wellcome Trust's Sir Jeremy Farrar and global government ministers, the group unites various stakeholders and aims to facilitate political discussions around the issue of AMR. **Allie Nawrat** digs deeper into this latest AMR initiative.

G20 leaders make historic commitment to combat AMR and TB in Declaration

10 July 2017 | Departmental news | Geneva | Reading time: 1 min (315 words)





A European One Health Action Plan against Antimicrobial Resistance (AMR)



Pharmaceutical Strategy for Europe

2020

Flagship initiatives related to antimicrobial resistance

- ▶ Pilot innovative approaches to EU R&D and public procurement for antimicrobials and their alternatives aiming to provide pull incentives for novel antimicrobials – target date 2021.
- ▶ Promote investment and coordinate research, development, manufacturing, deployment and use for novel antibiotics as part of the new EU Health Emergency Response Authority, prior to the start of the authority's operations preparatory action on AMR – 2021.



- ▶ Consider in the review of the pharmaceutical legislation¹ to introduce measures to restrict and optimise the use of antimicrobial medicines. Explore new types of incentives for innovative antimicrobials – 2022.



Other action

- ▶ Propose non-legislative measures and optimise the use of existing regulatory tools to combat antimicrobial resistance, including harmonisation of product information, draft evidence-based guidance on existing and new diagnostics; promote the prudent use of antibiotics and communication to healthcare professionals and patients – 2021.

L 387/8 Official Journal of the European Union 19.11.2020

COMMISSION IMPLEMENTING DECISION (EU) 2020/1729
of 17 November 2020
on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and
repealing Implementing Decision 2013/652/EU
(notified under document C(2020) 7894)
(Only the English version is authentic)
(Text with EEA relevance)



EU4Health programme for a healthier and safer Union

#EUBudget #EU4Health



1. References to the 'pharmaceutical legislation' are to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67) and Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).



3 July 2020
EMA/321483/2020



3.4. Antimicrobial resistance and other emerging health threats

Strategic goals


Based on its environmental analysis of the strategic area and the identified challenges, the Network has laid down six main goals to be achieved within the strategy period:

- 1) Provide high quality information on antimicrobial consumption and surveillance data on antimicrobial resistance in animals and humans in support of policy development.
- 2) Contribute to responsible use of antibacterial agents and effective regulatory antimicrobial stewardship in human and veterinary sectors by putting in place strategies to improve their use by patients, healthcare professionals and national authorities
- 3) Ensure regulatory tools are available that guarantee therapeutic options (with a focus on veterinary medicines) while minimising impact of antimicrobial resistance on public health and the environment
- 4) Define pull incentives for new and old antibacterial agents, including investigating support for new business models and not-for-profit development
- 5) Foster dialogue with developers of new antibacterial agents and alternatives to traditional antimicrobials, to streamline their development and provide adequate guidance in both human and veterinary medicine
- 6) Improve regulatory preparedness for emerging health threats

European medicines agencies network strategy to 2025

Protecting public health at a time of rapid change

Main EMA (h) activities to combat antimicrobial resistance



01

Update guidance to developers

02

Interact with international regulators

03

Focus on alternative therapies (other than antibiotics);

04

Role in prudent use of approved antibacterials


05

Make best use of regulatory tools to speed up approval for medicines addressing an unmet medical need

06

Early engagement with developers of medicines that tackle AMR

Stages in bringing new antimicrobials to market




Source: ECA adopted from COMBACTE managing entity (University Medical Centre Utrecht).

Discovery of new antibiotics

More than 30-Year Void in Discovery of New Types of Antibiotics

(Number of antibiotic classes discovered or patented)



Source: ECA based on "A sustained and robust pipeline of new antibacterial drugs and therapies is critical to preserve public health", Pew Charitable Trusts, May 2016.

1. EMA updates guidance to developers



- **EMA/CHMP/351889/2013** Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections
- **EMA/CHMP/594085/2015** Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products
- **EMA/CHMP/187859/2017** Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements.
- **EMA/CPMP/EWP/559/95 Rev 3 / 2019** Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections
- ✓ ***Several Scientific Advice Procedures over the last 7 years: more than in the previous 19 years***

EMA-FDA parallel SA



- **EMA/FDA Consultative Advice option** allows sponsors to request scientific advice from one regulatory agency and concurrently notify the other regulatory agency of the request
Independently from the above options, new development plans are mutually discussed between FDA, PMDA, HC and EMA on a monthly basis

Tripartite PMDA-FDA-EMA meetings 2016-2019 and further ones to be foreseen

2. EMA interacts with international regulators

Examples of agreement - cUTI

	FDA	EMA
Primary endpoint	Combined clinical and microbiologic response ($<1 \times 10^4$ CFU/mL) at TOC at least 5 days post completion of therapy; OR co-primary 5 days post-randomisation before PO switch and 7 days post-completion of therapy	Microbiological response ($<1 \times 10^3$ CFU/mL) at TOC 7 days post-completion of therapy, regardless of whether there was an IV/PO switch (based on requirement for $\geq 10^5$ CFU/mL at baseline)

Agreed proposal for convergence:
Clinical response and Microbiological response with a microbiological reduction cut-off at 1×10^3 CFU/mL

	FDA	EMA
Population	At least 30% patients with pyelonephritis (for an indication including pyelonephritis)	Separate trials in cUTI and pyelonephritis OR limit % with pyelonephritis and stratify

Agreed proposal for convergence: instead of conducting separate trials in cUTI and pyelonephritis, include both with at least 30% cUTI patients and at least 30% pyelonephritis patients

3. EMA focuses on alternative therapies

Bacteriophages


- Regulatory issues related to the need of changing the composition of the medicinal product over time. Lack of solid clinical data.

Monoclonal antibodies

- Variety of targets. Important to have proof of concept for specific activities. Zinplava approved in the EU for prevention of C.diff. Obiltoxaximab SFL approved in the EU for the treatment and post-exposure prophylaxis of anthrax

Vaccines for healthcare associated infections

- Scientific difficulties acknowledged. Target of future interactions with FDA. High potential impact in case of success.



ZinplavaTM
(bezlotoxumab)
Injection

1,000 mg/40 mL
(25 mg/mL)

For Intravenous Infusion Only


Requires dilution prior to administration.



Rx only

Single-dose vial. Discard unused portion.

4. EMA role on prudent use of antibiotics in humans



- Old and new antibacterial agents need to be preserved and used rationally, but regulators should not dictate criteria for clinical practice, e.g. by defining line of use for reasons other than benefit-risk
- Rapid diagnostics are a key area, however a pragmatic approach towards rapid diagnostics in the context of product information needs to be retained at this stage
- Modernisation of SmPCs of "old antibiotics" is the most valuable contribution to rational use, i.e. ensuring that updated Product information on indications of use, posology, is provided in a harmonised way for all EU healthcare professionals

5. EMA uses regulatory tools for medicines addressing unmet need

Tools in legislation

Conditional Marketing authorisation

- Based on less comprehensive data and with obligation to generate these data post-authorisation

Marketing authorisation under exceptional circumstances

- When comprehensive data can not be general at all, subject to specific obligations

Accelerated assessment

- Reduced assessment time for products of major public health interest

Compassionate use

- Products made available to patients prior granting of marketing authorisation

Other tools and initiatives

PRIME

- Support scheme with early and enhanced scientific dialogue

Adaptive pathways

- Scientific concept of medicines development and data generation

Innovation task force

- Forum for informal early dialogue

Early dialogue with EMA

- Other tools and initiatives

6. EMA engages early with developers to combat AMR

EMA facilitates early engagement with medicine developers to combat antimicrobial resistance



News 24/05/2019



As of today, EMA is opening up the early dialogue available through its [Innovation Task Force \(ITF\)](#) to all medicine developers who work on therapeutic approaches for the treatment or prevention of bacterial and fungal infections. ITF is a forum for dialogue between regulators and developers of innovative emerging therapies, methods and technologies, in the early stages of research and development. ITF is usually reserved for [innovative medicines](#). Given the growing threat to public health caused by [antimicrobial resistance](#) and the need for new treatments, EMA is inviting all developers working on medicines for the treatment or prevention of life-threatening microbial infections to enter into early dialogue with the Agency to help strengthen the drug development pipeline for new antimicrobials.

Support **innovative** drug development

Early informal dialogue with opinion leaders on

- **Scientific, legal and regulatory** issues
- **Products, methodologies and technologies**

Free of charge

Brainstorming “style” on innovation in areas without existing guidance

First step to engage is submit completed [3-page template](#)



New Veterinary Legislation: new tools to fight AMR

L 4/24

EN

Official Journal of the European Union

7.1.2019

REGULATION (EU) 2019/5 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 11 December 2018

amending Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, Regulation (EC) No 1901/2006 on medicinal products for paediatric use and Directive 2001/83/EC on the Community code relating to medicinal products for human use



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

31 October 2019
EMA/CVMP/158366/2019
Committee for Medicinal Products for Veterinary Use

Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans


Of relevance for HCPs:

EMA/CVMP advice:

- Criteria for the designation of antimicrobials to be reserved for human medicine

Many other important activities to tackle AMR (remember OneHealth!)

- AMR is a **major** growing public One Health threat
- Needs to be tackled **immediately** or we risk to going back to the pre-antibiotic era!
- Increased public and political awareness over the last decade
- Global and EU **cooperation and coordination** of measures is key
- EMA as the EU Regulator for Medicinal products fights AMR by:
 - Updating guidance to developers;
 - Interacting with international regulators;
 - Focusing on alternative therapies;
 - Promoting prudent use of approved antibacterials;
 - Making best use of regulatory tools to speed up approval for medicines addressing an unmet medical need;
 - Engaging with developers of medicines that tackle AMR;
 - Engaging with all relevant stakeholders





Any questions?

Radu.Botgros@ema.europa.eu

European Medicines Agency

Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands

Tel: +31 (0)88781 7690

Send a question via our website www.ema.europa.eu/contact

Follow us on  **@EMA_News**

Proposal for an EMA multistakeholder workshop on AMR

Scope

- One Health approach
- Focus on antibiotics Vs full range of antimicrobial resistance including antibiotics, antivirals, antifungals and antiparasitics
- Focus on what EMA has done/is doing; with participation of other EMA partners (e.g. EC, HERA, ECDC, EFSA, WHO)
- Stakeholder discussion on what can be done, gather feedback on Agency's direction and identify actions to be taken by other actors

Format

- One-day F2F meeting; by invitation only
- Live broadcast and recorded

Audience

- Human and Veterinary stakeholders
 - Representatives of patients, consumers and healthcare professional organisations, academia, pharmaceutical industry associations, HTA bodies, EMA and National Medicines Agencies, and international partners

Date

- 14 November 2023
- Followed by the PCWP/HCPWP annual meeting with all eligible organisations on 15 November 2023



Topics for discussion

- Comments on proposed scope
- Priorities to consider when drafting the agenda - identification of potential objectives
- Expectations from patients and healthcare professionals
- Potential contributions